24/7 Market News Snapshot 12 May, 2025 – Invivyd, Inc. Common Stock (NASDAQ:IVVD)

May 12, 2025

DENVER, Colo., 12 May, 2025 (www.247marketnews.com) – (Nasdaq:IVVD) are discussed in this article.
Invivyd, Inc. (Nasdaq:IVVD) is experiencing a significant surge in its stock price, opening at $0.706 and climbing by over 27% to $0.822, following a robust prior session close of $0.646. This uptick signals strong investor confidence and increased trading volume, now at 5.24 million shares. The heightened interest in IVVD stock may correlate with the company’s recent announcement regarding the initiation of a pioneering discovery program focused on developing a monoclonal antibody (mAb) intended for the treatment of active measles infections.

In light of declining vaccination rates, which leave more than 20 million individuals unvaccinated against measles in the U.S., the need for effective therapies is more urgent than ever. Currently, there are no approved treatments for measles, a reality that has raised serious public health concerns as complications can lead to severe illnesses such as pneumonia and encephalitis.

The new mAb program aims to fill this critical gap in healthcare. Distinguished experts, including infectious disease specialist Dr. Michael Mina, have highlighted the potential of monoclonal antibodies to neutralize viruses effectively while minimizing the side effects associated with traditional antiviral therapies. This innovation positions Invivyd to not only treat active infections but also offer preventive measures for vulnerable populations, particularly young children and immunocompromised individuals.

Marc Elia, Chairman of Invivyd’s Board of Directors, expressed optimism about this initiative, underscoring the company’s dedication to leveraging modern technologies in the quest for advanced treatments. Invivyd plans to identify and advance a preclinical measles mAb candidate by 2025, with updates on their developmental progress anticipated by the end of that year. This effort complements the company’s existing portfolio, which includes monoclonal antibodies designed for various viral infectious diseases, thereby reinforcing Invivyd’s commitment to addressing critical health challenges globally.

Related news for (IVVD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.